The FDA's Data on Mifepristone: A Trust Crisis

The FDA's reliance on questionable data for mifepristone raises serious concerns about the trustworthiness of its review process. Given the public scrutiny and legal battles surrounding the abortion pill, the agency must bolster its data integrity with rigorous, real-world evidence or risk undermining its credibility.